[go: up one dir, main page]

AR126153A1 - Una composición farmacéutica que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico - Google Patents

Una composición farmacéutica que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico

Info

Publication number
AR126153A1
AR126153A1 ARP220101577A ARP220101577A AR126153A1 AR 126153 A1 AR126153 A1 AR 126153A1 AR P220101577 A ARP220101577 A AR P220101577A AR P220101577 A ARP220101577 A AR P220101577A AR 126153 A1 AR126153 A1 AR 126153A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
indol
pyrazole
cyano
isopropyl
Prior art date
Application number
ARP220101577A
Other languages
English (en)
Inventor
Jieun Lee
Heemin Gwak
Seong Hye Shin
Ji Young Min
Min Hee Kim
Junyu Kim
Jung Youn Seo
June Sik Mune
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of AR126153A1 publication Critical patent/AR126153A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico o una sal farmacéuticamente aceptable de este, y un método para tratar o prevenir una enfermedad relacionada con la hiperuricemia usándolo, y la composición farmacéutica de la presente invención puede reducir de manera eficaz la concentración de ácido úrico en sangre en un paciente con una enfermedad relacionada con la hiperuricemia. Reivindicación 1: Una composición farmacéutica para tratar o prevenir una enfermedad relacionada con la hiperuricemia de un sujeto, caracterizada porque comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico o una sal farmacéuticamente aceptable de este, donde el ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico o una sal farmacéuticamente aceptable de este en la composición farmacéutica se administra por vía oral sujeto en una dosificación de 50 a 200 mg/día, El sujeto tiene una tasa de filtración glomerular estimada (eGFR) de menos de 90 mL/min/1,73 m².
ARP220101577A 2021-06-15 2022-06-15 Una composición farmacéutica que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico AR126153A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20210077709 2021-06-15

Publications (1)

Publication Number Publication Date
AR126153A1 true AR126153A1 (es) 2023-09-13

Family

ID=84525806

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220101577A AR126153A1 (es) 2021-06-15 2022-06-15 Una composición farmacéutica que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico

Country Status (17)

Country Link
US (2) US20240293369A1 (es)
EP (2) EP4360631A4 (es)
JP (2) JP2024520150A (es)
KR (2) KR20220168173A (es)
CN (2) CN117412746A (es)
AR (1) AR126153A1 (es)
AU (2) AU2022294728A1 (es)
BR (2) BR112023026432A2 (es)
CA (2) CA3221017A1 (es)
CL (2) CL2023003513A1 (es)
CO (2) CO2023016621A2 (es)
MX (2) MX2023014357A (es)
PE (2) PE20240241A1 (es)
PH (1) PH12023553231A1 (es)
TW (2) TWI901895B (es)
WO (2) WO2022265378A1 (es)
ZA (2) ZA202311237B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR126164A1 (es) * 2021-06-17 2023-09-27 Lg Chemical Ltd Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2133332E (pt) * 2007-04-11 2013-10-03 Kissei Pharmaceutical Derivado de (aza)indole e sua utilização para fins médicos
TWI423962B (zh) 2009-10-07 2014-01-21 Lg Life Sciences Ltd 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物
TWI548630B (zh) 2011-04-06 2016-09-11 Ｌｇ生命科學有限公司 １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法
TW201536284A (zh) 2013-05-31 2015-10-01 Teijin Pharma Ltd 使用黃嘌呤氧化酶抑制劑之治療方法與組成物
JP2015160847A (ja) * 2014-02-28 2015-09-07 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 小分子のキサンチンオキシダーゼ阻害剤および使用方法
CN106008488B (zh) * 2016-05-20 2018-10-30 广东东阳光药业有限公司 氰基吲哚类衍生物及其制备方法和用途
AU2018444285A1 (en) 2018-10-01 2021-05-20 Astrazeneca Ab Compositions for reducing serum uric acid
EP4257123A4 (en) 2020-12-01 2024-05-08 Lg Chem, Ltd. STABLE ORAL FORMULATION CONTAINING 1-(3-CYANO-1-ISOPROPYL-5-YL)PYRAZOLE-4-CARBOXYLIC ACID

Also Published As

Publication number Publication date
US20240285583A1 (en) 2024-08-29
TWI901895B (zh) 2025-10-21
ZA202311241B (en) 2025-03-26
AU2022294728A1 (en) 2024-01-04
MX2023014357A (es) 2023-12-15
JP2024520138A (ja) 2024-05-21
JP7668386B2 (ja) 2025-04-24
EP4344701A4 (en) 2024-10-23
CL2023003514A1 (es) 2024-05-03
CL2023003513A1 (es) 2024-06-07
TW202308611A (zh) 2023-03-01
CO2023016596A2 (es) 2023-12-11
BR112023026432A2 (pt) 2024-03-05
KR20220168172A (ko) 2022-12-22
US20240293369A1 (en) 2024-09-05
MX2023014359A (es) 2023-12-15
ZA202311237B (en) 2025-02-26
CA3221533A1 (en) 2022-12-22
JP2024520150A (ja) 2024-05-21
EP4360631A1 (en) 2024-05-01
EP4344701A1 (en) 2024-04-03
PE20240241A1 (es) 2024-02-16
CN117425477A (zh) 2024-01-19
WO2022265378A1 (ko) 2022-12-22
PH12023553231A1 (en) 2024-04-29
TWI888729B (zh) 2025-07-01
TW202304428A (zh) 2023-02-01
WO2022265382A1 (ko) 2022-12-22
AU2022292402A1 (en) 2023-12-14
CA3221017A1 (en) 2022-12-22
EP4360631A4 (en) 2025-05-21
BR112023026415A2 (pt) 2024-03-05
PE20240242A1 (es) 2024-02-16
KR20220168173A (ko) 2022-12-22
CN117412746A (zh) 2024-01-16
CO2023016621A2 (es) 2023-12-11

Similar Documents

Publication Publication Date Title
JP2023002662A5 (es)
JP5296557B2 (ja) 流涎症の治療のためのアルファ−２受容体アゴニスト（クロニジン）と抗ムスカリン剤（オキシブチニン）との組み合わせ
AR126153A1 (es) Una composición farmacéutica que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico
TW473389B (en) New pharmacological use of AII-receptor antagonists
JP7110196B2 (ja) カルバメート化合物を含む非経口用液剤
US10052281B2 (en) Local administration-type pharmaceutical for improving dysphagia
US6194466B1 (en) Use of metformin to counteract weight gain associated with valproate and other psychotropic medications
WO2021198940A1 (ja) ヒト又は動物の慢性若しくは急性のウイルス感染症及び／又は敗血症の予防若しくは治療のための組成物
CN1625402A (zh) 4－(2－氟苯基)－6－甲基－2－(1－哌嗪基)噻吩并(2,3－d)－嘧啶用于治疗尿失禁的用途
TWI391131B (zh) ３－（２，２，２－三甲基肼）丙酸鹽的新用途
US9974768B2 (en) Pharmaceutical for improving dysphagia
CN117379423A (zh) 依达拉奉在自闭症谱系障碍治疗中的应用
US20100324081A1 (en) Preventive, inhibitor or remedy for cerebral aneurysm comprising ibudilast as an active ingredient
US8952011B2 (en) Compositions and methods for the treatment of nasal conditions
WO2023201390A1 (en) Aqueous quetiapine solutions
US4757075A (en) Tetrazolylquinazolinones as anti-hyperuricemic agents
JP2025502488A (ja) イソキサゾリン誘導体を含む注射用製剤
CN116531358A (zh) 含乳酸盐缓冲体系在制备心力衰竭治疗药物中的应用
JP2021161105A (ja) ヒト又は動物の慢性若しくは急性のウイルス感染症及び／又は敗血症の予防若しくは治療のための組成物
CN1913894A (zh) 高血压症治疗药
JPWO2005117853A1 (ja) 高脂血症治療剤及び糖尿病治療剤
RU2003107504A (ru) Лекарственное средство для лечения хронического обструктивного бронхита

Legal Events

Date Code Title Description
FA Abandonment or withdrawal